US Pharma MarketingThe post Treeline and Roche collaborate on TLN-121 combo trial for BCL appeared first on Clinical Trials Arena.
Treeline and Roche collaborate on TLN-121 combo trial for BCL
Treeline Biosciences has signed a clinical trial collaboration and supply agreement with Roche for a Phase I study assessing the combination of Treeline’s BCL6 degrader, TLN-121, with Roche’s CD20×CD3 T-cell-engaging bispecific antibodies, glofitamab and mosunetuzumab, in patients with BCL. Treeline intends to start combination dosing in these cohorts in the fourth quarter of 2026. TLN-121 has shown single-agent activity, including complete responses, in Phase I trial in three late-line lymphomas. Credit: PanuShot / Shutterstock.com. Treeline Biosciences has signed a clinical trial collaboration and supply agreement with Roche for a Phase I study assessing the combination of Treeline’s BCL6 degrader, TLN-121,…
Treeline Biosciences has signed a clinical trial collaboration and supply agreement with Roche for a Phase I study assessing the combination of Treeline’s BCL6 degrader, TLN-121, with Roche’s CD20×CD3 T-cell-engaging bispecific antibodies, glofitamab and mosunetuzumab, in patients with BCL.
Source: Clinical Trials Arena